• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Hoth Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    5/27/26 8:33:47 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HOTH alert in real time by email
    false --12-31 0001711786 0001711786 2026-05-20 2026-05-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported) May 20, 2026

     

    Hoth Therapeutics, Inc. (Now Known As Rocket One Inc.)

    (Exact name of registrant as specified in its charter)

     

    Nevada   001-38803   82-1553794
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I. R. S. Employer
    Identification No.)

     

    720 Monroe Street, Suite E514

    Hoboken, NJ 07030

    (Address of principal executive offices, including ZIP code)

     

    (866) 239-7459

    (Registrant’s telephone number, including area code)

     

    Hoth Therapeutics, Inc.

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common stock, $0.0001 par value   RKTO   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

    Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    On May 20, 2026, Rocket One Inc. (formerly, Hoth Therapeutics, Inc.) (the “Company”) filed a Certificate of Amendment to its Articles of Incorporation, as amended (the “Charter Amendment”), with the Secretary of State of the State of Nevada to change the name of the Company from “Hoth Therapeutics, Inc.” to “Rocket One Inc.” effective as of May 26, 2026 (the “Name Change”). 

     

    Pursuant to Nevada Revised Statutes Section 78.390(8), no stockholder approval was required for the Charter Amendment because it only related to a name change. A copy of the Charter Amendment is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

     

    In connection with the Name Change, the Company’s trading symbol for its common stock will begin trading on The Nasdaq Capital Market on May 28, 2026 under the symbol “RKTO” (the “Symbol Change”).

     

    Neither the Name Change, nor the Symbol Change, affects the rights of the Company’s shareholders, and shareholders do not need to take any action in connection with the Name Change or the Symbol Change. The CUSIP number for the Company’s common stock will remain 44148G204.

     

    Item 8.01 Other Events.

     

    On May 27, 2026, the Company issued a press release announcing, among other things, the Name Change and Symbol Change. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

    As previously reported on a Current Report on Form 8-K filed with the SEC on May 6, 2026, on April 22, 2026, the Company filed Articles of Incorporation with the Secretary of State of the State of Nevada for the formation of its new wholly-owned subsidiary, Rocket One Inc. On May 20, 2026, the Company filed a Certificate of Amendment to the Articles of Incorporation with the Secretary of State of the State of Nevada to change the name of the subsidiary from “Rocket One Inc.” to “Rocket One.0 Inc.” effective as of May 26, 2026. 

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    The exhibit listed in the following Exhibit Index is filed as part of this Current Report on Form 8-K.

     

    Exhibit No.   Description of Exhibit
    3.1   Certificate of Amendment to Articles of Incorporation dated May 20, 2026
    99.1   Press release dated May 27, 2026
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     -1-

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: May 27, 2026 Rocket One Inc. (formerly Hoth Therapeutics, Inc.)
       
      /s/ Robb Knie
      Robb Knie
      Chief Executive Officer

     

     -2-

    Get the next $HOTH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HOTH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HOTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing for Space and Defense Applications

    Company Adopts Space-Focused Identity, New Ticker "RKTO," and Exclusive License of AI Chip Architecture Designed for Ultra-Low-Power, Radiation-Tolerant Computing in Space and Defense ApplicationsHOBOKEN, N.J., May 27, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("Hoth" or the "Company") today announced that, following the strategic repositioning disclosed on May 19, 2026, it has completed the legal change of its corporate name to Rocket One Inc. ("Rocket One") effective as of May 26, 2026 and will begin trading on The Nasdaq Capital Market under the new ticker symbol "RKTO" at the open of trading on May 28, 2026. The Company's common stock will cease trading under the symbol

    5/27/26 8:11:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform

    Allowed Claims Cover Composition-of-Matter and Methods Targeting MS4A6A Pre-mRNA Splicing to Reduce Surface Expression of the High-Affinity IgE Receptor (FcεRI); Strengthens Intellectual Property Foundation Underlying the HT-KIT Mast Cell ProgramHOBOKEN, N.J., May 26, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("Hoth" or the "Company"), a clinical-stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for Hoth's HT-KIT therapeutic. The allowed claims cover antisense oligomers of 25 to

    5/26/26 8:18:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of Exclusive Rights to Next Generation AI Semiconductor Acceleration Technology Built on Non-Volatile Nanomagnetic Semiconductor Architecture

    Company Targets Power Demands of AI Data Centers Through Patented Nanomagnetic Semiconductor and Spintronic Computing Technologies for AI, Defense, and Space ApplicationsHOBOKEN, N.J., May 19, 2026 /PRNewswire/ -- (NASDAQ:HOTH) ("Hoth" or the "Company") today announced that it intends to change its name to Rocket One, Inc. ("Rocket One"), and to restructure its business to position the Company, through its recently formed wholly-owned subsidiary, to pursue opportunities in artificial intelligence infrastructure, next-generation semiconductor technologies, and ultra-low-power AI computing.

    5/19/26 8:17:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Linsley Wayne

    4 - Rocket One Inc. (0001711786) (Issuer)

    5/28/26 4:16:25 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO and President Knie Robb

    4 - Rocket One Inc. (0001711786) (Issuer)

    5/28/26 4:15:59 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Sarnoff David

    4 - Rocket One Inc. (0001711786) (Issuer)

    5/28/26 4:15:42 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    SEC Filings

    View All

    Hoth Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Rocket One Inc. (0001711786) (Filer)

    6/3/26 8:27:22 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hoth Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Rocket One Inc. (0001711786) (Filer)

    6/3/26 8:26:22 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Hoth Therapeutics Inc.

    424B5 - Rocket One Inc. (0001711786) (Filer)

    6/3/26 8:25:17 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Knie Robb bought $16,750 worth of shares (25,000 units at $0.67), increasing direct ownership by 75% to 58,131 units (SEC Form 4)

    4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

    8/19/24 8:00:03 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    Leadership Updates

    Live Leadership Updates

    View All

    Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

    Company Expands IP Portfolio While Advancing Clinical Innovation in Oncology Supportive Care Case Study and Interim Clinical Trial Results Will Be Discussed NEW YORK, June 5, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company pioneering breakthrough therapies to improve the lives of patients, today announced a Key Opinion Leader (KOL) event showcasing HT-001, its novel topical therapeutic, designed to treat debilitating skin toxicities caused by EGFR inhibitor cancer therapies. These common treatment-limiting side effects—suc

    6/5/25 8:12:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hoth Therapeutics Announces the Appointment of John Cirrito, PhD and Carla Yuede, PhD to Oversee Alzheimer's Therapeutic Program as Part of Hoth Scientific Advisory Board

    NEW YORK, Jan. 31, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced the addition of John Cirrito, PhD and Carla Yuede, PhD to the Company's Scientific Advisory Board. While serving on the Board, Dr. Cirrito and Dr. Yuede will oversee the development of HT-ALZ, an oral therapeutic in development under the 505(b)(2) regulatory pathway for the treatment of Alzheimer's disease (AD) and symptoms associated with AD. Mr. Robb Knie, CEO of Hoth Therapeutics, commented, "Hoth is extremely pleased to welcome Dr. Cir

    1/31/22 8:17:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Hoth Therapeutics Inc. (Amendment)

    SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)

    2/14/24 2:47:32 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Hoth Therapeutics Inc.

    SC 13G - Hoth Therapeutics, Inc. (0001711786) (Subject)

    2/14/23 12:55:35 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Hoth Therapeutics Inc. (Amendment)

    SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)

    2/8/23 6:07:04 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care